IL-15 is a cytokine with potential therapeutic application in individuals with cancer or immunodeficiency to promote NK-and T-cell activation and proliferation or in vaccination protocols to generate long-lived memory T-cells. Here we report that 10-50 µg/kg of IL-15 administered intravenously daily for 12 days to rhesus macaques has both short-and long-lasting effects on T-cell homeostasis. Peripheral blood lymphopenia preceded a dramatic expansion of NK-cells and memory CD8 T-cells in the circulation, particularly a fourfold expansion of central memory CD8 T-cells and a sixfold expansion of effector memory CD8 T-cells. This expansion is a consequence of their activation in multiple tissues. A concomitant inverted CD4/CD8 T-cell ratio was observed throughout the body at day 13, a result of preferential CD8 expansion. Expanded T and NK-cell populations declined in the blood soon after IL-15 was stopped, suggesting migration to extralymphoid sites. By day 48, homeostasis appears restored throughout the body with the exception of the maintenance of an inverted CD4/CD8 ratio in lymph nodes. Thus, IL-15 generates a dramatic expansion of short-lived memory CD8 T-cells and NK-cells in immunocompetent macaques and has long-term effects on the balance of CD4 + and CD8 + T-cells.
Introduction
Cytokines belonging to the γ-chain family represent a promising tool for the treatment of certain human diseases in which the immune system is suppressed like HIV or cancer. Thus, boosting immunity in these patients may be beneficial and result in improved treatment. is part of the γ-chain family of cytokines and exerts multiple effects on different populations of the immune system. For instance, it is necessary for NK-cell development since IL-15-deficient mice lack NK-cells 1, 2 ; it acts as an NK growth factor by promoting the differentiation of CD56 + cytokineproducing NK-cells to CD56 -CD16 + cytotoxic NK-cells 3 . Conversely, IL-15 is not required for T-cell development but exerts a fundamental role in determining their survival and homeostasis in the periphery. IL-15 -/-or IL-15 receptor α chain (IL-15Rα) -/-mice display slightly reduced numbers of naïve T-cells and a selective deficiency of memory T-cells 1, 2 . Indeed, IL-15 is important for memory T-cell homeostasis as mediates the expansion and maintenance of memory-phenotype CD8 + T-cells 4 and the homeostatic proliferation of antigen-specific CD8 + T-cells, while survival is mainly mediated by IL-7 in the latter case 4, 5 . IL-15 also acts on memory CD4 + T-cells and cooperates with IL-7 in inducing their expansion in non-lymphopenic conditions 4 .
A unique biological mechanism governs IL-15 functions in vivo, as the cytokine is transpresented by cells bearing IL-15Rα chain to neighboring cells which, in turn, express CD122 (IL-15Rβ chain) and CD132 (common γ chain, shared by other cytokines such as IL-2, IL-7, IL-9 and IL-21), which are necessary for IL-15 signaling in responding cells 6, 7 ) . Activated monocytes or dendritic cells can express IL-15Rα and produce the cytokine at the same time: IL-15 can thus be mounted on the receptor in intracellular compartment and then translocated to the cell surface 6 . IL-15Rα on Tcells and NK-cells is dispensable for IL-15 responsiveness, as IL15Rα-deficient CD8 + T-cells behave normally when transferred to wild-type mice 8 .
Previous studies of IL-15 administration to rhesus macaques (RM) revealed that the cytokine was well tolerated and did not induce any severe side effect if given subcutaneously 9, 10 . A recent study macaques daily received s.c. injections of glycosylated IL-15, i.e. produced in a mammalian system, for a total of 8 days (d) at doses ranging from 2.5 to 15 μg/Kg found that animals displayed reversible . In these reports, IL-15 was able to efficiently expand memory-phenotype T-cells and NK-cells but, in uncontrolled SIV infection, little effect was seen on memory CD4 + T-cells 9, 10 . By contrast, when SIV-uninfected or ART-controlled SIV + monkeys are treated with bacterial-produced IL-15, a strong proliferative burst is observed in the CD4 + transitional or effector memory compartment in the peripheral blood, with little or no effect on other CD4 + subsets 10 ; central memory T-cell expansion could be induced after administration of glycosylated IL-15
11
. Responding CD4 + and CD8 + cells transiently expanded in the peripheral blood and subsequently localized to the bronchoalveolar space 10 .
Still, little is known about the kinetics of the response and on the migration/persistence of expanded cells in the whole body. In this paper, we analyzed T and NK-cell dynamics in multiple tissues upon treatment daily treatment with IL-15 in RM and show that it generates a much more massive expansion of NK-and memory T-cells compared to previous studies in which an intermittent, twice-a-week administration was considered 9, 11, 12 . Surprisingly, however, expanded cells did not For personal use only. on October 28, 2017. by guest www.bloodjournal.org From
Material and Methods

Experimental design
Recombinant human interleukin-15 (rhIL-15) was administered intravenously to 8 groups of rhesus macaques using a computerized randomization procedure. All animal studies were approved by the NIH IACUC. The first 4 groups received 10 μg/kg, 20 μg/kg or 50 μg/kg of rhIL-15 intravenously daily from day one through day 12 and underwent necropsy on day 13, one day after the last dose.
Group 4 received formulation buffer, i.e., at a volume equivalent on a per Kg basis to the volume administered to the high-dose group on the same dosing and necropsy schedule as group one. The remaining 12 animals received 10, 20 and 50 μg of rhIL-15 or formulation buffer at the same dose and dosing schedule with the exception that they underwent necropsy on day 48 (36 days after the last dose). FACS analysis was performed on 7-10 mL of EDTA-anticoagulated blood 7 days prior to the start of the study and then on days 8 and 13 for the animals sacrificed on day 13 and on 7 days prior to the start of the study and then on days 8, 15, 22, 29 and 48 the date of necropsy.
Preparation of rhIL-15
Recombinant human interleukin-15 (rhIL-15) was produced under current good manufacturing practice (cGMP) conditions in an E. coli system. rhIL-15 was produced as a nonglycosylated single-chain polypeptide of 115 amino acids having a calculated molecular weight of 12,901 Da. In this work an E. coli based fermentation and purification process was developed for the production of clinical grade recombinant human IL-15. DNA sequences for human IL-15 inserted into the pET 28 b plasmid were expressed in the E. coli host BL 21-AL. The inclusion bodies of IL-15 produced in E. coli were solubilized, refolded and orthogonally purified to yield active IL-15.
Purification consisted of orthogonal column chromatography and filtration methods that included Superdex-200 chromatography, refolding of denatured rhIL-15, Butyl HIC chromatography, source 15Q chromatography, Qxl chromatography and Superdex-75 chromatography to produce the sterile filtered pure drug substance formulated in 25 mM sodium phosphate and 500 mM sodium chloride pH For personal use only. on October 28, 2017. by guest www.bloodjournal.org From 7.4. The sterile filtered bulk drug substance was then filled into vials to produce the final vialed product.
Isolation of mononuclear cells (MNCs) from blood tissues
Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll density gradient centrifugation, according to standard techiniques. At the time of necropsy the following tissues were collected: lymph nodes (mesenteric, MLN; axillary, ALN; inguinal, ILN), spleen (Spl), bone marrow (BM) and jejunum (Jej). Briefly, LN specimens were minced thouroughly, resuspended in RPMI 1640 containing 2 μg/mL collagenase D (Roche), then incubated for 30 minutes at 37°C. Cell suspesion was passed multiple times through a 16-gauge needle and then through a 70 μg cell strainer. Spleen was chopped and mashed thoroughly; MNCs were subsequently isolated by Ficoll. Jejunal samples were chopped and digested 3-5 times in R10 (RPMI1640 supplemented with 10% FCS and 1% penicyllin-streptomycin and 1% L-glutamine) containing 0.5 mg/mL collagenase II (Sigma-Aldrich, St. Louis, MO) for 30 min at 37°C. Supernatant was then layered onto a 35%/65% Percoll gradient for the isolation of MNCs. Cells were immediately frozen in fetal bovine serum + 10% DMSO and put in liquid nitrogen until analysis.
Antibodies and flow cytometry
All unconjugated antibodies were purchased from BD Biosciences. Non-fluorescent antibodies were conjugated in our laboratory according to the protocols reported at http://www.drmr.com/abcon. Rhesus MNCs were used to titrate reagents. For phenotypic analysis, frozen PBMCs were thawed in R10 containing Benzonase nuclease (EMD Biochemicals, San Diego, CA), extensively washed and stained immediately with the Violet Viability Dye (VIVID; Invitrogen, Carlsbad, CA) in PBS for 15 min at RT. Cells were then washed and stained with the combination of antibodies indicated in Suppl. Table I for 20 minutes at RT. Differently, CD132, CCR5 and CCR7 were stained for 20 minutes at 37°C to improve surface detection 13 . CD122 expression was revealed by biotin-conjugated antibody followed by staining with streptavin-Qdot 655. For the analysis of 
Assessment of T and NK intracellular cytokine production
Frozen cells were thawed in R10 containing benzonase (Novagen, Darmstadt, Germany) and rested for 4h at 37 C before stimulation. For the assessment of T cell cytokine production, 0.5x10 6 PBMC were stimulated with 1 μg/mL SEB or left unstimulated (DMSO alone). For the assessment of NK cell cytokine production, 1.5x10 6 PBMC were stimulated with the MHC class I-deficient cell line 721.221 at the E:T ratio of 5:1, 100 ng/mL IL-15 and 500 UI IL-2 (both from Peprotech, Rock Hill, NJ). Cells in medium alone served as control. In both cases, GolgiPlug (BD Biosciences) was added 1h later to block cytokine secretion and cells were cultured for additional 12h. Cells were then surface stained with monoclonal antibodies to lineage antigens, subsequently fixed and permeabilized with 
Results
Transient lymphopenia precedes T-and NK-cell expansion in the peripheral blood
We assessed the effect of three different doses of daily recombinant human IL-15 adminstered intravenously for 12 days in a cohort of 24 Indian rhesus macaques. The cytokine was well tolerated with no major side effects. The only clinical meaningful abnormality observed in the toxicology study was a grade 3/4 neutropenia in approximately half of the animals receiving 20 or 50 μg/kg doses. The neutropenia observed only during the course of IL-15 therapy appears to represent a redistribution of neutrophils from the blood pool to the tissues. A complete description of the pathology and toxicity is presented elsewhere (T. A. Waldmann, manuscript in preparation). We next assessed the effect of the cytokine on the absolute lymphocyte count in the peripheral blood. As shown in Fig.1 , IL-15-treated macaques displayed a decrease in the peripheral lymphocyte count at d2 after injection, which then increased at d8, reached its maximum peak at d13 or d15, returned to baseline at d22 and remained stable for the remaining follow-up period. A similar kinetic was observed for the absolute count of
CD8
+ and CD4 + T-cells and NK-cells. Expansion was cell-type dependent, yielding a more dramatic expansion in total NK-cells and CD8 + T-cells (~6 fold expansion compared to pretreatment for both populations), than for total CD4 + T-cells (~2.5 fold increase). Surprisingly, B-cell counts decreased in the peripheral blood with the same kinetic after initiation of the treatment and only recovered at d48, while the CD14 + monocyte was mildly increased. Notably, we did not see a consistent dose-dependent relationship to these dynamics between 10 and 50 μg/Kg.
IL-15 preferentially expands CD16 + NK-cells and effector memory phenotype T-cells
To better define the NK and T-cell subsets that are specifically expanded by IL-15 in RMs, we carried out an extensive analysis of NK-and T-cell differentiation status. We used anti-CD56 and and was maintained until d15 (three days after the last IL-15 dose). The absolute count of both subsets returned to baseline one week later and remained stable for the remaining follow-up period.
Evaluation of multiple NK receptor expression (the lectin-type receptor NKG2D (activatory) and NKG2A (inhibitory); the natural cytotoxicity receptor NKp46; the C-type lectin receptor NKp80) on a subset of animals (n=2) receiving 50 μg/Kg/day IL-15 ( T-cell differentiation status was revealed by the simultaneous analysis of CD45RA, CD95, CCR7 and CD28 antigens in CD4 + and CD8 + T-cells, as depicted in Fig.2c . Fig.2d shows that the absolute counts of all CD4 + and CD8 + memory subsets were expanded upon cytokine treatment.
However, T EM with an ~ 8 fold increase compared to pretreatment expanded the most. The kinetics of expansion mirrored those observed for total CD4 + and CD8 + T-cell counts, with a peak observed at d13 after the first administration. Little effect was observed on CD4 + and CD8 + T N cells, compared to other memory subsets (~2 fold expansion at d13). Interestingly, before treatment, the expression of CD122, but not of CD132, among lymphocyte subsets reflected the hierarchy of expansion in the blood at the peak of expansion (Suppl. Fig.1 ), even though a correlation between CD122 MFI and the expression of Ki-67 at d8 was not seen (data not shown).
We then evaluated the proliferation and activation state of T N (CCR7 + CD95 -), T CM (preferentially CD8 + ) after administration ( Fig.3a and 3b ). Upregulation of these antigens followed the hierarchy of expansion observed in the peripheral blood, that is CD8>CD4 and T EM >T CM >>T N . IL-15 also induced some of its own receptor subunits in responding cells, as CD122 (IL-15Rβ chain) and CD132 (IL-15Rγ chain) increased during the treatment, then declined after treatment was stopped (Fig.3b) . No changes in the expression of CCR5 and HLA-DR were detected (data not shown).
Long-term changes of the cytokine production capacity of NK cells after IL-15 treatment
We next evaluated the quality of the cytokine production of T cells and NK cells after .3a ).
Suppl. Fig.3b shows that IL-15 efficiently expanded Tregs in the blood by ~3 fold with the same kinetics observed for other T-cell subsets. The majority of Tregs was Ki-67 + even before treatment with IL-15 and their proportion augmented after cytokine administration. Increase in the frequency of this population was also observed in all tissues at d13 and they were found to be proliferating, as revealed by the increased Ki-67 expression (Suppl. Fig.3c ). However, their proportion and Ki-67 expression did not differ from control animals at d48 after treatment, indicating that there was no preferential long-term expansion of Tregs over conventional T-cells with restoration of homeostasis (Suppl. Fig.3c ).
The markers used in this study to define Treg cells can, at least in humans, be induced after Tcell activation. For this reason, it is possible that expansion of the phenotypic Treg cells might just reflect T-cell activation and proliferation induced by treatment with the cytokine. To test this hypothesis, we correlated the percentage of Tregs in tissues at d13 with the fraction of T CM or T EM CD4 + or CD8 + T-cells that expressed Ki-67 or CD38 at the same time point and found no direct correlation (data not shown). In the blood, the increased count of Tregs did not influence expansion of T-cell subsets as no correlation was found with the fold increase in the absolute of T CM or T EM cells at
For personal use only. on October 28, 2017. by guest www.bloodjournal.org From d8 after the initiation of the treatment (data not shown). These data suggest that IL-15 might act directly on the subset of naturally occurring Tregs but their increased frequency does not limit expansion of conventional T-cell subsets.
Effect of IL-15 administration on DC subsets and NKT cells.
The frequency of dendritic cell (DC) subsets, i.e. myeloid (m) DC and plasmacytoid (p) DC, were also monitored in the peripheral blood and in different body sites. pDCs and mDCs were identified as depicted in Suppl. Fig.4a . Suppl. Fig.4b shows that mDC cell count increased after IL-15 treatment and then returned to baseline after treatment was stopped. By contrast, pDC cell count decreased at d8, suggesting redistribution to other tissues, and normalized at d15. DC subsets were thus investigated in multiple tissues at d13 and d48 after treatment but no changes were detected at these time points (data not shown). IL-15 treatment did not induce maturation of mDCs and pDCs, as revealed by the measurement of CD80 and CD86 molecules on their surface (data not shown). IL-15 can be produced by DCs or monocytes and transpresented to targeT-cells after being mounted on IL-15Rα and expressed on the cell surface 6 . However, we did not observe any modulation of the receptor expression on these cells and we failed to see the expression of the cytokine on their surface by using an anti-IL-15 monoclonal antibody (data not shown).
We also evaluated whether IL-15 was able to preferentially expand NKT cells, defined as CD14 -CD20 -CD3 + Vα24 + that bind to the PBS57-CD1d tetramer, but saw no changes in proportion or cell counts during and after treatment in the peripheral blood (Suppl. Given the strong proliferation and activation of memory cells in the tissues, especially CD8 + T-cells, we expected an increased absolute lymphocyte count in these sites. This was also suggested by an increase at d13 in both the T:B cell ratio (i.e. the ratio between the percentage of cells expressing CD3 and CD20 in the lymphocyte gate) and NK:B-cell ratio (i.e. cells expressing either CD56 or CD16 and CD20) in the spleen (Fig.5a ) but not in other sites (data not shown). Moreover, perturbation of the CD4:CD8 ratio in favor of CD8 + T-cells occurred in the MLN and a similar trend could be observed in all tissues except the jejunum (Fig.5a) . Finally, at the same time point, the spleen and the liver were respectively 425% and 85% bigger in size in the 50 μg/Kg-treated than in the sham-treated macaques and histological analysis revealed that these organs were infiltrated with lymphocytes (T. A. Waldmann, manuscript in preparation). Nonetheless, fine analysis of T-cell differentiation revealed no changes in the proportion of total memory cells (Fig.5b) , despite
+ cells), as we observed a decreased proportion of T CM and a parallel increase of T TM or T EM cells (Fig.5c ).
The same organs were also investigated at autopsy at d13 for the presence of NK-cells to check whether they were expanded after IL-15 treatment. As in the blood, two main subsets of NKcells were quantified (Fig.5d) . We showed that IL-15 treatment induced expansion of T-cells and NK-cells in the blood as a result of the stimulation in peripheral tissues. NK-and T-cell increases in the blood were transient and declined after IL-15 treatment was stopped ( Fig.1 and Fig.2 ). Daily doses of IL-15 resulted in a greater expansion of these cells but could not maintain elevated T-and NK-cell counts in the blood.
We thus hypothesized that expanded cell subsets selectively localize to peripheral tissues at a later time point. Surprisingly, at d48, no differences were seen in the proportion of NK-cells vs. B-cells or T-cells vs. B-cells in IL-15-treated animals (Fig.6a) . Similarly, in these animals, the percentage of the two major subsets of NK-cells relative to the total lymphocyte population or the percentage of total memory cells relative to CD4 + or CD8 + subsets did not change in any of the tissues analyzed (Fig.6b) .
Moreover, no preferential expansion/localization of specific memory T-cell subset could be found in peripheral tissues in animals that received IL-15 (data not shown). These data led us to hypothesize that the concomitant induction of cell death could be induced as a consequence of IL-15 stimulation.
To test this, we cultured peripheral blood cells, from two animals that received the 50 μg/Kg/day dose, with no additional stimuli to mimic cytokine withdrawal in vivo. We analyzed the expression of annexin V (anxV), a early maker of cell death, at 24 and 48 hours. Suppl. Fig.7 
Despite most of the homeostatic parameters returned to baseline levels at d48 after treatment, the CD4:CD8 ratio remained inverted in different sites of the body, such as the MLN or the ALN (P<0.05 IL-15 vs. Sham; Fig.6c ) and the same trend could be observed in the ILN. Interestingly, this parameter normalized in other tissues (Fig.6c) and in the peripheral blood (P>0.05 IL-15-treated animals at d48 vs. d-7; Fig.6d ). These data indicate that IL-15 administration generates T and NKcells that apparently cannot persist for long term but induces chronic changes in the balance of CD4 + and CD8
+ T-cells in the body.
For
Discussion
The total number of lymphocytes in the body is tightly regulated and the immune system triggers different homeostatic mechanisms to restore it after acute fluctuations 20 . In lymphopenic conditions, e.g. after bone marrow or stem cell transplantation, T-cells show increased proliferation rates in response to the so-called homeostatic cytokines, mainly IL-7 21 . This process is generally slow and it takes months or even years to bring the total T-cell number back to normality. In some experimental conditions, lymphocyte turnover can be greatly altered such as when T-cells are transferred into lymphopenic mice and undergo massive homeostatic proliferation due to high levels of homeostatic cytokines 22 . Alteration in the lymphocyte turnover can be also induced by pharmacological doses of cytokines. Indeed, NK-cell and T-cell expansion in response to IL-15 has been previously demonstrated by other studies in RM [9] [10] [11] [12] . However, the present paper describes two novel aspects of IL-15 pharmacology and immunobiology.
First, we demonstrated that a daily administration for 12 days induces a much greater expansion of CD8 + T cells and NK cells than following the intermittent, twice-a-week administration, as reported in previous studies (~6 fold vs. ~1.5-3 fold) 9 ,11,12 . Interestingly, we did not see a dosedependent effect of the cytokine on the expansion of NK and T cell subsets in the PB, with the 10 μg/Kg dose being equivalent to the 20 μg/Kg dose (Fig. 2) . Furthermore, at these doses, similar effects on T cells were observed in terms of induction of Ki-67 and multiple activation markers (Fig.   3) , and in the functionality of T and NK cells (Suppl. Fig. 2) . Moreover, the lack of neutropenia observed after administration of 10 μg/Kg IL-15 suggests that this dose could be optimal for inducing NK and T cell expansion while maintaining minimal side effects in humans.
Second, by carefully investigating the complex dynamics of NK-and T-cell subsets in multiple tissue specimens at early and late time points after treatment, we show that IL-15 targets NKand memory T-cells in several tissues but expanded cells are short-lived and do not persist for longterm. Strikingly, while the naïve/memory T-cell balance was rapidly restored after treatment in all tissues analyzed, the CD4:CD8 balance remained altered in the LN, even at d48 after administration.
At d2 after IL-15 injection, macaques experienced transient lymphopenia (Fig.7b) , which preceded TFor personal use only. on October 28, 2017. by guest www.bloodjournal.org From and NK-cell expansion at d8. This seems to be a common effect of other cytokines of the γ-chain family, since early lymphopenia has been also described after administration of IL-7 23,24 and IL-21 25,26 . Redistribution of lymphocytes early after therapy thus indicates that stimulation by IL-15 occurs in peripheral tissues rather than in the circulation. Expanded lymphocytes are then rapidly released and account for the increased T-and NK-cell count and for the decreased naïve/memory cell balance in the blood (Fig.7b) .
The increased NK:CD20 ratio and CD3:CD20 ratio in the spleen at d13 corroborate the suggestion that there is an increased lymphocyte number in peripheral tissues. This is also supported by the fact that, in high dose IL-15-treated animals, the weight of the spleen (increase in size by 425%) or the liver (increase in size by 85%) was much higher than in untreated animals, which was associated with an infiltration of lymphocytes (T. A. Waldmann, manuscript in preparation). Notably, all body sites except the jejunum displayed an inverted CD4:CD8 ratio at this time point. This is consistent with the fact that CD8 + T-cells are the main targets of IL-15-induced expansion. However, why is the total T-cell pool not increasing in the lymph nodes or in the bone marrow at d13 despite the Although we do not have a direct demonstration, we believe that the dynamics described above also govern NK-cell expansion and homeostasis after treatment with IL-15. In this case, it is difficult to determine whether CD56 -CD16 + cells are generated from the CD56 + CD16 -counterpart, although the two subsets followed different kinetics shortly after therapy (Fig.2b) For Dynamics of T N and memory T-cell subset counts in the peripheral blood after treatment with IL-15.
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